+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Diabetes Drug Market Report by Drug class, Diabetes types, Route of Administration, Distribution Channels, Region and Company Analysis 2024-2032

  • PDF Icon

    Report

  • 230 Pages
  • May 2024
  • Region: Global
  • Renub Research
  • ID: 5562695
Global Diabetes Drug Market size is anticipated to be almost US$ 107.02 Billion by 2032. The CAGR for the global diabetes drug market from 2024 to 2032 is 6.06%. The publisher states that it equalled to US$ 63.02 Billion in 2023.

An excessively high blood glucose, or blood sugar, level is known as diabetes. The meals people eat provide them with glucose. Glucose is a necessary energy source for bodily cells. Insulin is a hormone that facilitates the uptake of glucose into the cells. Insulin is a diabetes medication that people with type 1 diabetes must take to manage their blood sugar. Some individuals with type 2 diabetes can manage their blood sugar with physical activity and a nutritious diet. For some, though, a diabetic diet and exercise regimen are insufficient. They must take medication for diabetes. The type of diabetes, daily activities, medication expenses, and any additional medical issues all influence the sort of medication a person takes. They can require the use of multiple diabetes medications over time.

Global Diabetes Drug Market Trends

Increase in the Prevalence of Diabetes

Diabetes is a costly and fatal illness. The World Health Organization (WHO) estimates that 422 million people worldwide have diabetes, and the disease is directly responsible for 1.5 million fatalities annually. The diabetic drug market is predicted to develop due to the rise of diabetes types. According to The Lancet, by 2050, there may be more than 1•31 billion diabetics on the planet. That translates to 1.31 billion people worldwide who suffer from a disease that can change their quality of life, has significant fatality rates, and interacts with or exacerbates numerous other illnesses. Currently, 90% of cases of diabetes are caused by type 2 diabetes. The NIH estimates there were 500,000 new instances of type 1 diabetes that year out of 8.4 million people living with the disease worldwide. The estimated 13.5-27.4 million individuals with T1DM will exist by 2040.

Public Awareness Campaigns add to the growth of the diabetic drug industry

Many public awareness-raising initiatives have been put into place throughout the years to try and avoid diabetes and its complications. The Pan American Health Organization stated that only roughly 50% of individuals with type 2 diabetes receive the necessary insulin, frequently due to financial constraints on their nation's healthcare systems. Many initiatives are developed by different organizations to aid with these issues. This is driving the worldwide diabetes drugs market. The World Health Organization's "Access to Diabetes Care" campaign, launched on World Diabetes Day in 2023, emphasized the need for fair access to essential healthcare services, including medication, technology, and support. It also aimed to increase public knowledge of strategies for lowering the risk of complications for those with diabetes. Events also honored the stories of those with diabetes in all its forms, encouraging those affected to take action by locating and accessing necessary medical care.

Product approvals propel the worldwide diabetes drug market

Diabetes is still a primary medical concern because of its rising incidence throughout the world and the strong correlations between chronic hyperglycemic states and obesity, liver disease, and several cardiovascular illnesses. The US Food and Drug Administration (FDA) has authorized and withdrawn several medication regimens for diabetes treatment since the early discovery of insulin. The global diabetes drug industry is predicted to rise with this rise in product approvals. One example is the approval of bexagliflozin (Brenzavvy, TheracosBio) by the US Food and Drug Administration (FDA) for treating adult type 2 diabetes in January 2023.

United States Diabetes Drug Market

The United States is expected to dominate the global diabetes drug market due to its increasing prevalence. The estimates from the US Census Bureau say that about 37 million Americans, both adults and children, are reportedly impacted. The American Diabetes Association estimates that 352,000 Americans under the age of 20 have been diagnosed with diabetes, or roughly 0.35% of the total population. It was projected that 5,300 people had type 2 diabetes and 18,200 people had type 1 diabetes among young people with a diagnosis per year.

The worldwide diabetic drug industry is developing as new medications are created to provide diabetic patients with additional treatment options due to the disease's rising prevalence. For example, U.S. regulators will allow the sale of a new version of the well-known diabetic medicine Mounjaro as a weight-loss medication in November 2023. The United States Food and Drug Administration has approved Eli Lilly's Zepbound or tripeptide. According to a recent study, medication-assisted dieters lost 60 pounds (27 kilograms), or almost 25% of their body weight.

Global Diabetes Drug Company News

The global diabetes drug industry constitutes Novo Nordisk, AstraZeneca plc, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb Co., and Novartis AG.
  • In January 2024 - Glenmark Pharmaceuticals Ltd. introduced a biosimilar version of the well-known anti-diabetic Ligutide in India. The medication is being sold under the LirafitTM brand after receiving approval from the Drug Controller General of India (DCGI). This will reduce therapy costs by about 70% and be available only with a prescription. It will cost about INR 100 for a regular dose of 1.2 mg per day.
  • In December 2023 - The U.S. weight-loss medication manufacturer Carmot Therapeutics, which creates diabetic and anti-obesity medications, is set to be acquired by Swiss pharmaceutical company Roche for US$ 2.7 Billion.
  • In November 2023 - AstraZeneca entered the weight-loss drug market with a bang, signing an exclusive license deal with a Chinese startup for a type 2 diabetes and obesity medication still in the early stages of development.
  • In October 2023 - Glenmark Pharmaceuticals launched a triple-fixed-dose combination (FDC) drug to treat diabetes. The Mumbai-based drug firm introduced the combination of Teneligliptin, Dapagliflozin, and Metformin under the brand name Zita.
  • In August 2023 - Lupin expanded its diabetic portfolio by acquiring Germany's GmbH's Ondero and Ondero Met.

Drugs Class - Market breakup in 5 viewpoints:

1. Insulin
2. GLP-1 Receptor Agonists
3. DPP-4 Inhibitors
4. SGLT2 Inhibitors
5. Others

Diabetes Types - Market breakup in 2 viewpoints:

1. Type 1 Diabetes
2. Type 2 Diabetes

Route of Administration - Market breakup in 3 viewpoints:

1. Oral
2. Subcutaneous
3. Intravenous

Distribution Channels - Market breakup in 4 viewpoints:

1. Colonoscope Hospital Pharmacies
2. Rental Pharmacies
3. Online Pharmacies
4. Others

Country - Market breakup of 25 Countries:

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

  • Overview
  • Recent Development
  • Revenue Analysis

Company Analysis:

1. Novo Nordisk
2. AstraZeneca plc
3. Biocon, Sanofi
4. Eli Lilly
5. Johnson & Johnson
6. Bristol Myers Squibb Co.
7. Novartis AG

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Diabetes Drugs Market
6. Global Diabetes Drugs Market Share Analysis
6.1 By Drugs Class
6.2 By Diabetes Types
6.3 By Route of Administration
6.4 By Distribution Channels
6.5 By Countries
7. Drugs Class - Global Diabetes Drugs Market
7.1 Insulin
7.2 GLP-1 Receptor Agonists
7.3 DPP-4 Inhibitors
7.4 SGLT2 Inhibitors
7.5 Others
8. Diabetes Types - Global Diabetes Drugs Market
8.1 Type 1 Diabetes
8.2 Type 2 Diabetes
9. Route of Administration - Global Diabetes Drugs Market
9.1 Oral
9.2 Subcutaneous
9.3 Intravenous
10. Distribution Channels - Global Diabetes Drugs Market
10.1 Hospital Pharmacies
10.2 Rental Pharmacies
10.3 Online Pharmacies
10.4 Others
11. Countries - Global Diabetes Drugs Market
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherlands
11.2.8 Turkey
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina
11.5 Middle East & Africa
11.5.1 Saudi Arabia
11.5.2 United Arab Emirates
11.5.3 South Africa
12. Diabetes Drugs Clinical Trial & Development
12.1 Key Players Analysis
12.1.1 Enavogliflozin (Phase III): Daewoong
12.1.1.1 Product Description
12.1.1.2 Research and Development
12.1.1.3 Product Development Activities
12.1.2 Golimumab (Phase II): Janssen Biotech
12.1.2.1 Product Description
12.1.2.2 Research and Development
12.1.2.3 Product Development Activities
12.1.3 IMCY-0098 (Phase II/I): ImCyse
12.1.3.1 Product Description
12.1.3.2 Research and Development
12.1.3.3 Product Development Activities
12.2 Pre-clinical evaluation and discovery phase
12.2.1 ENT-001: Enthera
12.2.1.1 Product Description
12.2.1.2 Research and Development
12.2.1.3 Product Development Activities
13. Porter's Five Forces Analysis - Global Diabetes Drugs Market
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Competition
13.4 Threat of New Entrants
13.5 Threat of Substitutes
14. SWOT Analysis - Global Diabetes Drugs Market
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats
15. Key Players Analysis
15.1 Novo Nordisk
15.1.1 Overview
15.1.2 Recent Development
15.1.3 SWOT Analysis
15.1.4 Sales Analysis
15.2 AstraZeneca plc
15.2.1 Overview
15.2.2 Recent Development
15.2.3 SWOT Analysis
15.2.4 Sales Analysis
15.3 Biocon
15.3.1 Overview
15.3.2 Recent Development
15.3.3 SWOT Analysis
15.3.4 Sales Analysis
15.4 Sanofi
15.4.1 Overview
15.4.2 Recent Development
15.4.3 SWOT Analysis
15.4.4 Sales Analysis
15.5 Eli Lilly
15.5.1 Overview
15.5.2 Recent Development
15.5.3 SWOT Analysis
15.5.4 Sales Analysis
15.6 Johnson & Johnson
15.6.1 Overview
15.6.2 Recent Development
15.6.3 SWOT Analysis
15.6.4 Sales Analysis
15.7 Bristol Myers Squibb Co.
15.7.1 Overview
15.7.2 Recent Development
15.7.3 SWOT Analysis
15.7.4 Sales Analysis
15.8 Novartis AG
15.8.1 Overview
15.8.2 Recent Development
15.8.3 SWOT Analysis
15.8.4 Sales Analysis
List of Tables
Table-01: Global - Diabetes Drugs Market Share by Drugs Class (Percent), 2019 - 2023
Table-02: Global - Forecast for Diabetes Drugs Market Share by Drugs Class (Percent), 2024 - 2032
Table-03: Global - Diabetes Drugs Market Share by Diabetes Types (Percent), 2019 - 2023
Table-04: Global - Forecast for Diabetes Drugs Market Share by Diabetes Types (Percent), 2024 - 2032
Table-05: Global - Diabetes Drugs Market Share by Route of Administration (Percent), 2019 - 2023
Table-06: Global - Forecast for Diabetes Drugs Market Share by Route of Administration (Percent), 2024 - 2032
Table-07: Global - Diabetes Drugs Market Share by Distribution Channels (Percent), 2019 - 2023
Table-08: Global - Forecast for Diabetes Drugs Market Share by Distribution Channels (Percent), 2024 - 2032
Table-09: Global - Diabetes Drugs Market Share by Countries (Percent), 2019 - 2023
Table-10: Global - Forecast for Diabetes Drugs Market Share by Countries (Percent), 2024 - 2032
List of Figures
Figure-01: Global - Diabetes Drugs Market (Billion US$), 2019 - 2023
Figure-02: Global - Forecast for Diabetes Drugs Market (Billion US$), 2024 - 2032
Figure-03: Drugs Class - Insulin Market (Million US$), 2019 - 2023
Figure-04: Drugs Class - Forecast for Insulin Market (Million US$), 2024 - 2032
Figure-05: Drugs Class - GLP-1 Receptor Agonists Market (Million US$), 2019 - 2023
Figure-06: Drugs Class - Forecast for GLP-1 Receptor Agonists Market (Million US$), 2024 - 2032
Figure-07: Drugs Class - DPP-4 Inhibitors Market (Million US$), 2019 - 2023
Figure-08: Drugs Class - Forecast for DPP-4 Inhibitors Market (Million US$), 2024 - 2032
Figure-09: Drugs Class - SGLT2 Inhibitors Market (Million US$), 2019 - 2023
Figure-10: Drugs Class - Forecast for SGLT2 Inhibitors Market (Million US$), 2024 - 2032
Figure-11: Drugs Class - Others Market (Million US$), 2019 - 2023
Figure-12: Drugs Class - Forecast for Others Market (Million US$), 2024 - 2032
Figure-13: Diabetes Types - Type 1 Diabetes Market (Million US$), 2019 - 2023
Figure-14: Diabetes Types - Forecast for Type 1 Diabetes Market (Million US$), 2024 - 2032
Figure-15: Diabetes Types - Type 2 Diabetes Market (Million US$), 2019 - 2023
Figure-16: Diabetes Types - Forecast for Type 2 Diabetes Market (Million US$), 2024 - 2032
Figure-17: Route of Administration - Oral Market (Million US$), 2019 - 2023
Figure-18: Route of Administration - Forecast for Oral Market (Million US$), 2024 - 2032
Figure-19: Route of Administration - Subcutaneous Market (Million US$), 2019 - 2023
Figure-20: Route of Administration - Forecast for Subcutaneous Market (Million US$), 2024 - 2032
Figure-21: Route of Administration - Intravenous Market (Million US$), 2019 - 2023
Figure-22: Route of Administration - Forecast for Intravenous Market (Million US$), 2024 - 2032
Figure-23: Distribution Channels - Hospital Pharmacies Market (Million US$), 2019 - 2023
Figure-24: Distribution Channels - Forecast for Hospital Pharmacies Market (Million US$), 2024 - 2032
Figure-25: Distribution Channels - Rental Pharmacies Market (Million US$), 2019 - 2023
Figure-26: Distribution Channels - Forecast for Rental Pharmacies Market (Million US$), 2024 - 2032
Figure-27: Distribution Channels - Online Pharmacies Market (Million US$), 2019 - 2023
Figure-28: Distribution Channels - Forecast for Online Pharmacies Market (Million US$), 2024 - 2032
Figure-29: Distribution Channels - Others Market (Million US$), 2019 - 2023
Figure-30: Distribution Channels - Forecast for Others Market (Million US$), 2024 - 2032
Figure-31: United States - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-32: United States - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-33: Canada - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-34: Canada - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-35: France - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-36: France - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-37: Germany - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-38: Germany - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-39: Italy - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-40: Italy - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-41: Spain - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-42: Spain - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-43: United Kingdom - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-44: United Kingdom - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-45: Belgium - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-46: Belgium - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-47: Netherlands - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-48: Netherlands - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-49: Turkey - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-50: Turkey - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-51: China - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-52: China - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-53: Japan - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-54: Japan - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-55: India - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-56: India - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-57: South Korea - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-58: South Korea - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-59: Thailand - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-60: Thailand - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-61: Malaysia - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-62: Malaysia - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-63: Indonesia - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-64: Indonesia - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-65: Australia - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-66: Australia - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-67: New Zealand - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-68: New Zealand - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-69: Brazil - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-70: Brazil - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-71: Mexico - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-72: Mexico - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-73: Argentina - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-74: Argentina - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-75: Saudi Arabia - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-76: Saudi Arabia - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-77: United Arab Emirates - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-78: United Arab Emirates - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-79: South Africa - Diabetes Drugs Market (Million US$), 2019 - 2023
Figure-80: South Africa - Forecast for Diabetes Drugs Market (Million US$), 2024 - 2032
Figure-81: Novo Nordisk - Global Revenue (Million US$), 2019 - 2023
Figure-82: Novo Nordisk - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-83: AstraZeneca plc - Global Revenue (Million US$), 2019 - 2023
Figure-84: AstraZeneca plc - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-85: Biocon - Global Revenue (Million US$), 2019 - 2023
Figure-86: Biocon - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-87: Sanofi - Global Revenue (Million US$), 2019 - 2023
Figure-88: Sanofi - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-89: Eli Lilly - Global Revenue (Million US$), 2019 - 2023
Figure-90: Eli Lilly - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-91: Johnson & Johnson - Global Revenue (Million US$), 2019 - 2023
Figure-92: Johnson & Johnson - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-93: Bristol Myers Squibb Co. - Global Revenue (Million US$), 2019 - 2023
Figure-94: Bristol Myers Squibb Co. - Forecast for Global Revenue (Million US$), 2024 - 2032
Figure-95: Novartis AG - Global Revenue (Million US$), 2019 - 2023
Figure-96: Novartis AG - Forecast for Global Revenue (Million US$), 2024 - 2032

Companies Mentioned

  • Novo Nordisk
  • AstraZeneca plc
  • Biocon, Sanofi
  • Eli Lilly
  • Johnson & Johnson
  • Bristol Myers Squibb Co.
  • Novartis AG

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Table Information